These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 32307659)

  • 1. Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals.
    Drudge-Coates L; Van den Wyngaert T; Schiødt M; van Muilekom HAM; Demonty G; Otto S
    Support Care Cancer; 2020 Sep; 28(9):4019-4029. PubMed ID: 32307659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
    Otto S; Pautke C; Van den Wyngaert T; Niepel D; Schiødt M
    Cancer Treat Rev; 2018 Sep; 69():177-187. PubMed ID: 30055439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medication-related osteonecrosis of the jaw: knowledge and perceptions of medical professionals on the usage of bone modifying agents and dental referrals.
    Acharya S; Patil V; Ravindranath V; Kudva A; Nikhil K
    J Med Life; 2022 Mar; 15(3):368-373. PubMed ID: 35449990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current knowledge regarding medication-related osteonecrosis of the jaw among different health professionals.
    Miranda-Silva W; Montezuma MA; Benites BM; Bruno JS; Fonseca FP; Fregnani ER
    Support Care Cancer; 2020 Nov; 28(11):5397-5404. PubMed ID: 32144584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How we manage medication-related osteonecrosis of the jaw.
    Byrne H; O'Reilly S; Weadick CS; Brady P; Ríordáin RN
    Eur J Med Res; 2024 Aug; 29(1):402. PubMed ID: 39095845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment.
    Nicolatou-Galitis O; Schiødt M; Mendes RA; Ripamonti C; Hope S; Drudge-Coates L; Niepel D; Van den Wyngaert T
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2019 Feb; 127(2):117-135. PubMed ID: 30393090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
    Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
    Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MASCC/ISOO Clinical Practice Statement: Adjuvant bone-modifying agents in primary breast cancer patients - prevention of medication-related osteonecrosis of the jaw.
    Yarom N; Van Poznak CH; Epstein JB; Ottaviani G; Matsuda Y; Migliorati C; Elad S
    Support Care Cancer; 2024 Jul; 32(8):547. PubMed ID: 39048887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interventions for managing medication-related osteonecrosis of the jaw.
    Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O; Peter JU
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD012432. PubMed ID: 35866376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral risk factors associated with medication-related osteonecrosis of the jaw in patients with cancer.
    Ueda N; Aoki K; Shimotsuji H; Nakashima C; Kawakami M; Imai Y; Kirita T
    J Bone Miner Metab; 2021 Jul; 39(4):623-630. PubMed ID: 33420576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study.
    Hasegawa T; Hayashida S; Kondo E; Takeda Y; Miyamoto H; Kawaoka Y; Ueda N; Iwata E; Nakahara H; Kobayashi M; Soutome S; Yamada SI; Tojyo I; Kojima Y; Umeda M; Fujita S; Kurita H; Shibuya Y; Kirita T; Komori T;
    Osteoporos Int; 2019 Jan; 30(1):231-239. PubMed ID: 30406309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication-Related Osteonecrosis of the Jaw: A Cross-Sectional Study on the Prevalence of Cutaneous Manifestations and the Primary Care Physician's Role in its Early Diagnosis.
    Whitefield S; Ilan MB; Lazarovici TS; Friedlander-Barenboim S; Kassem R; Yarom N
    Am J Med; 2024 Mar; 137(3):266-272. PubMed ID: 38042241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.
    Anastasilakis AD; Pepe J; Napoli N; Palermo A; Magopoulos C; Khan AA; Zillikens MC; Body JJ
    J Clin Endocrinol Metab; 2022 Apr; 107(5):1441-1460. PubMed ID: 34922381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical and Dental Professions' Varying Levels of Awareness Regarding Medication-related Osteonecrosis of the Jaw in Saudi Arabia? A Cross-sectional Study.
    Aljohani MH; Aljohani AS; Aljohani RM; Alsharif WK; Nourwali I; Elsayed SA
    J Contemp Dent Pract; 2024 Jan; 25(1):62-67. PubMed ID: 38514433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnosis and treatment of medication-related osteonecrosis of the jaws from an oncologist's perspectives].
    Yuan P
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2021 May; 56(5):415-420. PubMed ID: 33904274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical status of established MRONJ in oncology patients continuing bone-modifying agents.
    Miles E; Arya R; Sproat C; Patel V
    Br Dent J; 2024 May; 236(9):683-687. PubMed ID: 38730156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does inflammatory dental disease affect the development of medication-related osteonecrosis of the jaw in patients using high-dose bone-modifying agents?
    Ueda N; Nakashima C; Aoki K; Shimotsuji H; Nakaue K; Yoshioka H; Kurokawa S; Imai Y; Kirita T
    Clin Oral Investig; 2021 May; 25(5):3087-3093. PubMed ID: 33057886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline.
    Yarom N; Shapiro CL; Peterson DE; Van Poznak CH; Bohlke K; Ruggiero SL; Migliorati CA; Khan A; Morrison A; Anderson H; Murphy BA; Alston-Johnson D; Mendes RA; Beadle BM; Jensen SB; Saunders DP
    J Clin Oncol; 2019 Sep; 37(25):2270-2290. PubMed ID: 31329513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRONJ in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case series.
    Mauceri R; Coppini M; Attanasio M; Bedogni A; Bettini G; Fusco V; Giudice A; Graziani F; Marcianò A; Nisi M; Isola G; Leonardi RM; Oteri G; Toro C; Campisi G
    BMC Oral Health; 2023 Feb; 23(1):71. PubMed ID: 36739399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.
    Ikesue H; Mouri M; Tomita H; Hirabatake M; Ikemura M; Muroi N; Yamamoto S; Takenobu T; Tomii K; Kawakita M; Katoh H; Ishikawa T; Yasui H; Hashida T
    Support Care Cancer; 2021 Aug; 29(8):4763-4772. PubMed ID: 33527228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.